Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal irinotecan added to mFOLFOX4 and bevacizumab for unresectable colorectal peritoneal metastases
NL-OMON58612Phase 2Active, not recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, oxaliplatin, fluorouracil, folinic acid and bevacizumab in colorectal cancer (CRC) and peritoneal carcinomatosis (PC), sponsored by Catharina Ziekenhuis. Primary endpoints: Overall survival from diagnosis of peritoneal metastases and Overall survival from first treatment cycle. Started Jun 2026; status: active, not recruiting.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acidbevacizumab
03
Conditions
colorectal cancer (CRC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NL-OMON58612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58612.